AstraZeneca, Daiichi Sankyo Say European Medicines Agency Validates Enhertu Application for Breast Cancer

MT Newswires Live01-20

AstraZeneca (AZN) and Daiichi Sankyo said Monday the European Medicines Agency has validated the type II variation marketing authorization application for their drug, Enhertu, as a first-line treatment for patients with HER2-positive metastatic breast cancer.

The validation was based on a 1,157-patient phase 3 trial result that showed Enhertu in combination with pertuzumab "significantly improved" progression-free survival, compared with current first-line standard of care in HER2-positive inoperable or metastatic breast cancer, the companies said.

The validation launches the scientific review process for the indication by Europe's Committee for Medicinal Products for Human Use.

Enhertu was discovered by Daiichi Sankyo and is being jointly developed and commercialized by the company and AstraZeneca.

Shares of AstraZeneca were down over 3% in recent premarket activity Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604994981?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604994981","market":"fut","top_or_hot":-1,"title":"AstraZeneca, Daiichi Sankyo Say European Medicines Agency Validates Enhertu Application for Breast Cancer","media":"MT Newswires Live","content":"<html><body><p> AstraZeneca (AZN) and <a href=\"https://laohu8.com/S/DSKY\">Daiichi Sankyo</a> said Monday the European Medicines Agency has validated the type II variation marketing authorization application for their drug, Enhertu, as a first-line treatment for patients with HER2-positive metastatic breast cancer.</p><p>The validation was based on a 1,157-patient phase 3 trial result that showed Enhertu in combination with pertuzumab \"significantly improved\" progression-free survival, compared with current first-line standard of care in HER2-positive inoperable or metastatic breast cancer, the companies said.</p><p>The validation launches the scientific review process for the indication by Europe's Committee for Medicinal Products for Human Use.</p><p>Enhertu was discovered by <a href=\"https://laohu8.com/S/DSKYF\">Daiichi Sankyo</a> and is being jointly developed and commercialized by the company and AstraZeneca.</p><p>Shares of AstraZeneca were down over 3% in recent premarket activity Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca, Daiichi Sankyo Say European Medicines Agency Validates Enhertu Application for Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca, Daiichi Sankyo Say European Medicines Agency Validates Enhertu Application for Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-20 18:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AstraZeneca (AZN) and <a href=\"https://laohu8.com/S/DSKY\">Daiichi Sankyo</a> said Monday the European Medicines Agency has validated the type II variation marketing authorization application for their drug, Enhertu, as a first-line treatment for patients with HER2-positive metastatic breast cancer.</p><p>The validation was based on a 1,157-patient phase 3 trial result that showed Enhertu in combination with pertuzumab \"significantly improved\" progression-free survival, compared with current first-line standard of care in HER2-positive inoperable or metastatic breast cancer, the companies said.</p><p>The validation launches the scientific review process for the indication by Europe's Committee for Medicinal Products for Human Use.</p><p>Enhertu was discovered by <a href=\"https://laohu8.com/S/DSKYF\">Daiichi Sankyo</a> and is being jointly developed and commercialized by the company and AstraZeneca.</p><p>Shares of AstraZeneca were down over 3% in recent premarket activity Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2604994981","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604994981","pubTimestamp":1768903429,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AstraZeneca  and Daiichi Sankyo said Monday the European Medicines Agency has validated the type II variation marketing authorization application for their drug, Enhertu, as a first-line treatment for patients with HER2-positive metastatic breast cancer.The validation was based on a 1,157-patient phase 3 trial result that showed Enhertu in combination with pertuzumab \"significantly improved\" progression-free survival, compared with current first-line standard of care in HER2-positive inoperable or metastatic breast cancer, the companies said.The validation launches the scientific review process for the indication by Europe's Committee for Medicinal Products for Human Use.Enhertu was discovered by Daiichi Sankyo and is being jointly developed and commercialized by the company and AstraZeneca.Shares of AstraZeneca were down over 3% in recent premarket activity Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4568":"美国抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","MDCO":"麦迪逊医药","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","AZN":"阿斯利康","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4007":"制药"},"translate_title":"阿斯利康、第一三共表示欧洲药品管理局验证Enhertu治疗乳腺癌的申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"MDCO":1.5},"content_text":"AstraZeneca (AZN) and Daiichi Sankyo said Monday the European Medicines Agency has validated the type II variation marketing authorization application for their drug, Enhertu, as a first-line treatment for patients with HER2-positive metastatic breast cancer.The validation was based on a 1,157-patient phase 3 trial result that showed Enhertu in combination with pertuzumab \"significantly improved\" progression-free survival, compared with current first-line standard of care in HER2-positive inoperable or metastatic breast cancer, the companies said.The validation launches the scientific review process for the indication by Europe's Committee for Medicinal Products for Human Use.Enhertu was discovered by Daiichi Sankyo and is being jointly developed and commercialized by the company and AstraZeneca.Shares of AstraZeneca were down over 3% in recent premarket activity Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604994981","isCrawlerRequest":true}